»ï¼º¼­¿ïº´¿ø ÀåÁØÈ£ ±³¼ö, µ¿³²¾Æ 3±¹ ¼øȸ ÃÊû¿¬ÀÚ Âü¼®

´º½ºÀÏÀÚ: 2009³â03¿ù24ÀÏ 00½Ã00ºÐ

¼º±Õ°üÀÇ´ë »ï¼º¼­¿ïº´¿ø Ç÷¾×Á¾¾ç³»°ú ÀåÁØÈ£ ±³¼ö°¡ 15ÀϺÎÅÍ 19ÀϱîÁö Àεµ³×½Ã¾Æ, ¸»·¹À̽þÆ, ű¹ µî µ¿³²¾Æ 3°³±¹ ÃÊûÀ¸·Î ÇöÁö¸¦ ¹æ¹®ÇØ °ñ¼öÇü¼ºÀÌ»óÁõÈıº Ä¡·á¿¡ °üÇÑ ÃÖ½ÅÁö°ßÀ» ÃÊû°­¿¬Çß´Ù.

ÀåÁØÈ£ ±³¼ö´Â 3¿ù 15ÀÏ Àεµ³×½Ã¾Æ ÀÚÄ«¸£Å¸¿¡¼­ °ñ¼öÇü¼ºÀÌ»óÁõÈıº ¿öÅ·ÆÄƼ(MDS working party) ÃÊûÀ¸·Î ‘Focus on epigenetic treatment and patient management’¸¦ ÁÖÁ¦·Î °­¿¬ÇßÀ¸¸ç, 3¿ù 17ÀÏ ¸»·¹À̽þƿ¡¼­´Â ‘Korean experience in epigenetic therapy’¸¦ ÁÖÁ¦·Î, 3¿ù 19ÀÏ Å±¹¿¡¼­´Â ‘Hypomethylating agents improves myeoldysplastic syndrome treatment’ ÁÖÁ¦·Î ÃÊû°­¿¬À» ÁøÇàÇß´Ù.

Àå ±³¼ö´Â À̹ø µ¿³²¾Æ 3±¹ ¼øȸ ÃÊû°­¿¬À» ÅëÇØ ±×µ¿¾È °ñ¼öÇü¼ºÀÌ»óÁõÈıº(myeoldysplastic syndrome)ÀÇ Ç³ºÎÇÑ ÀÓ»ó°æÇèÀ» ÇöÁö ±¹°¡ ÀÇ·áÁø°ú °øÀ¯ÇÏ°í ÃֽŠġ·á¹ý µîÀ» °­¿¬ÇÔÀ¸·Î½á ¿ì¸®³ª¶ó ÀÇÇмöÁØÀÇ À§»óÀ» ³Î¸® ¾Ë¸®´Âµ¥ Å« ±â¿©¸¦ ÇÑ °ÍÀ¸·Î Æò°¡¹Þ°í ÀÖ´Ù.

 


ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.